On February 25, 2021 Harbour BioMed (HBM) (HKEX: 02142) reported that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HBM4003, the next generation anti-CTLA-4 antibody in combination with PD-1 antibody/chemotherapy for the treatment of patients with advanced NSCLC and solid tumors (Press release, Harbour BioMed, FEB 25, 2021, View Source [SID1234575705]). This study will evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 in combination with PD-1 antibody, with or without chemotherapy in patients with advanced NSCLC and other solid tumors. Professor Shun Lu, Chairman of Chinese Society of Lung Cancer in China Anti-Cancer Association, Chief Key Program Expert of Ministry of Science and Technology of the People´s Republic of China, Director of Oncology Department at Shanghai Chest Hospital, will be the leading PI of this study. HBM4003 has already received US FDA and China NMPA IND approvals of the mono therapy, as well as another combination therapy in China, and has completed patient dosing in several patients in its ongoing phase I study in Australia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The NMPA’s IND approval of HBM4003 for clinical trial in lung cancer is a significant leap forward in our global development plans for HBM4003. It has already demonstrated encouraging safety and anti-tumor activity in patients in our ongoing trials," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "Across the world, lung cancer remains the leading cause of cancer incidence and mortality, with over 2 million new cases in 2020. There are over 1 million patients in China alone and we look forward to bringing this novel combination therapeutic to these patients soon."
About HBM4003
HBM4003 is the fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice. HBM4003 shows enhanced antibody-dependent cell cytotoxicity (ADCC) killing activity and is extremely specific to CTLA-4High Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug.